CStone keeps cool head to seal $285m Hong Kong IPO
CStone Pharmaceuticals will list Hong Kong’s first biotech IPO of 2019 next week, getting things moving with a deal that bankers said is a sign of a maturing market after 2018's rush of deals.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: